Preclinical Models and New Therapeutic Agents Unit, Regina Elena National Cancer Institute, Rome, Italy.
Institute of General Pathology, Catholic University, Rome, Italy.
Cell Death Differ. 2017 Oct;24(10):1811-1820. doi: 10.1038/cdd.2017.121. Epub 2017 Jul 14.
The limited clinical response to conventional chemotherapeutics observed in colorectal cancer (CRC) may be related to the connections between the hyperactivated β-catenin signaling and other pathways in CRC stem-like cells (CRC-SC). Here, we show the mechanistic link between the endothelin-1 (ET-1)/ET-1 receptor (ET-1R) signaling and β-catenin pathway through the specific interaction with the signal transducer β-arrestin1 (β-arr1), which initiates signaling cascades as part of the signaling complex. Using a panel of patient-derived CRC-SC, we show that these cells secrete ET-1 and express ETR and β-arr1, and that the activation of ETR/β-arr1 axis promotes the cross-talk with β-catenin signaling to sustain stemness, epithelial-to-mesenchymal transition (EMT) phenotype and response to chemotherapy. Upon ETR activation, β-arr1 acts as a transcription co-activator that binds β-catenin, thereby promoting nuclear complex with β-catenin/TFC4 and p300 and histone acetylation, inducing chromatin reorganization on target genes, such as ET-1. The enhanced transcription of ET-1 increases the self-sustained ET-1/β-catenin network. All these findings provide a strong rationale for targeting ET-1R to hamper downstream β-catenin/ET-1 autocrine circuit. Interestingly, treatment with macitentan, a dual ETR and ETR antagonist, able to interfere with tumor and microenvironment, disrupts the ET-1R/β-arr1-β-catenin interaction impairing pathways involved in cell survival, EMT, invasion, and enhancing sensitivity to oxaliplatin (OX) and 5-fluorouracil (5-FU). In CRC-SC xenografts, the combination of macitentan and OX or 5-FU enhances the therapeutic effects of cytotoxic drugs. Together, these results provide mechanistic insight into how ET-1R coopts β-catenin signaling and offer a novel therapeutic strategy to manage CRC based on the combination of macitentan and chemotherapy that might benefit patients whose tumors show high ETR and β-catenin expression.
在结直肠癌(CRC)中观察到的传统化疗的有限临床反应可能与过度激活的β-连环蛋白信号与 CRC 干细胞样细胞(CRC-SC)中的其他途径之间的联系有关。在这里,我们通过与信号转导β-抑制蛋白 1(β-arr1)的特异性相互作用,显示了内皮素-1(ET-1)/内皮素受体(ET-1R)信号与β-连环蛋白途径之间的机制联系,β-arr1 作为信号转导复合物的一部分启动信号级联。使用一组患者来源的 CRC-SC,我们表明这些细胞分泌 ET-1 并表达 ETR 和 β-arr1,并且 ETR/β-arr1 轴的激活促进与β-连环蛋白信号的串扰以维持干细胞特性、上皮-间质转化(EMT)表型和对化疗的反应。在 ETR 激活后,β-arr1 作为转录共激活子与β-连环蛋白结合,从而促进与β-catenin/TFC4 和 p300 的核复合物和组蛋白乙酰化,诱导靶基因上的染色质重排,如 ET-1。增强的 ET-1 转录增加了自我维持的 ET-1/β-连环蛋白网络。所有这些发现为靶向 ET-1R 以阻碍下游β-连环蛋白/ET-1 自分泌回路提供了强有力的依据。有趣的是,用 macitentan 治疗,一种双重 ETR 和 ETR 拮抗剂,能够干扰肿瘤和微环境,破坏 ET-1R/β-arr1-β-连环蛋白相互作用,损害涉及细胞存活、EMT、侵袭的途径,并增强对奥沙利铂(OX)和 5-氟尿嘧啶(5-FU)的敏感性。在 CRC-SC 异种移植物中,macitentan 和 OX 或 5-FU 的联合使用增强了细胞毒性药物的治疗效果。总之,这些结果深入了解了 ET-1R 如何招募β-连环蛋白信号,并提供了一种新的治疗策略,基于 macitentan 和化疗的联合治疗结直肠癌,可能使那些肿瘤表达高 ETR 和β-连环蛋白的患者受益。